Age Expansion Indication for Cibinqo Clinical Prior Authorization Criteria Effective May 31, 2023

On May 31, 2023, HHSC will implement the new age expansion indication for Cibinqo (abrocitinib) to update the cytokine and cell-adhesion molecule (CAM) antagonist clinical prior authorization. The age expansion will include adolescents 12 through 18 years of age whose atopic dermatitis is not adequately controlled with other systemic drugs, including biologics, or when other therapies are not advised. The U.S. Food and Drug Administration recently approved this age expansion.

The cytokine and CAM antagonist clinical prior authorization (PDF) is optional for MCOs.